jcmt
Search

Hot Keywords
Biomarker Discovery Autophagy and Cancer Breast Cancer Metastasis Brain Metastases Gastric Cancer Metastasis Lung Cancer Genetic Heterogeneity Colorectal Cancer Prostate Cancer Cancer Immunotherapy Circulating Tumor Cells Neuroendocrine Tumors

Top
  1. Home
  2. The paper's citation list
The paper's citation list
No.The paper's citation list
1Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment. 2020;16:62 doi: 10.2174/1573394715666190913184853
2Neurologische Nebenwirkungen von Checkpoint-Inhibitoren. 2019;90:138 doi: 10.1007/s00115-018-0571-8
3Space-velocity thermostatted kinetic theory model of tumor growth. 2021;18:5525 doi: 10.3934/mbe.2021279
4Cell density quantification with TurboSPI: R2* mapping with compensation for off-resonance fat modulation. 2020;33:469 doi: 10.1007/s10334-019-00817-4
5Exploiting Cancer’s Tactics to Make Cancer a Manageable Chronic Disease. 2020;12:1649 doi: 10.3390/cancers12061649
6Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives. 2021;19: doi: 10.1186/s12951-021-00861-0
7Immunotherapy. 2020;1244:255 doi: 10.1007/978-3-030-41008-7_13
8Recent Progress of Alkyl Radicals Generation‐Based Agents for Biomedical Applications. 2021;10:2100055 doi: 10.1002/adhm.202100055
9Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. 2020;6:29 doi: 10.1007/s40883-019-00113-6
10Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas. 2020;12:432 doi: 10.3390/cancers12020432
11Cancer Biology and Advances in Treatment. 2020;1292:113 doi: 10.1007/5584_2020_522
12Drug Repurposing for Triple-Negative Breast Cancer. 2020;10:200 doi: 10.3390/jpm10040200
13Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. 2021;173:281 doi: 10.1016/j.addr.2021.03.015
14Cancer immunotherapy: Recent advances and challenges. 2021;17:834 doi: 10.4103/jcrt.JCRT_1241_20
15Systems Medicine. 2021;593 doi: 10.1016/B978-0-12-801238-3.11605-8
16Bovine Dialyzable Leukocyte Extract IMMUNEPOTENT-CRP Induces Selective ROS-Dependent Apoptosis in T-Acute Lymphoblastic Leukemia Cell Lines. 2020;2020:1 doi: 10.1155/2020/1598503
17Cell Interaction - Molecular and Immunological Basis for Disease Management. 2021; doi: 10.5772/intechopen.94560
18Recent Progress in the Synergistic Combination of Nanoparticle‐Mediated Hyperthermia and Immunotherapy for Treatment of Cancer. 2021;10:2001415 doi: 10.1002/adhm.202001415
19A Hepatitis B Virus-Derived Peptide Exerts an Anticancer Effect via TNF/iNOS-producing Dendritic Cells in Tumor-Bearing Mouse Model. 2021;13:407 doi: 10.3390/cancers13030407
20The emergence of drug resistance to targeted cancer therapies: Clinical evidence. 2019;47:100646 doi: 10.1016/j.drup.2019.100646
21Immunotherapy. 2018;995:131 doi: 10.1007/978-3-030-02505-2_6
22Immunotherapies and Combination Strategies for Immuno-Oncology. 2020;21:5009 doi: 10.3390/ijms21145009
23Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine. 2021;13:133 doi: 10.1080/19466315.2020.1814403
24Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. 2018;50:1 doi: 10.1038/s12276-018-0115-0
25Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. 2020;9:2967 doi: 10.3390/jcm9092967
26Recent advances in localized immunotherapy of skin cancers. 2019;11:443 doi: 10.2217/imt-2018-0139
27Principles of Tumors. 2020;453 doi: 10.1016/B978-0-12-816920-9.00018-3
28CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. 2018;6:105 doi: 10.3390/biomedicines6040105
29Bioactive Nanoparticles for Cancer Immunotherapy. 2018;19:3877 doi: 10.3390/ijms19123877
30MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. 2019;303:223 doi: 10.1016/j.jconrel.2019.04.019
31Systemic anticancer therapies and the role of primary care. 2020;31:22 doi: 10.1002/psb.1871
32Checkpoint inhibitors: What gastroenterologists need to know. 2018;24:5433 doi: 10.3748/wjg.v24.i48.5433
33Pembrolizumab: The Nut Cracker. 2020;41:393 doi: 10.4103/ijmpo.ijmpo_37_20
34Peptide-based targeting of immunosuppressive cells in cancer. 2020;5:92 doi: 10.1016/j.bioactmat.2020.01.006
35Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments. 2020;49:726 doi: 10.1080/08820139.2020.1748047
36Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. 2020;106:104722 doi: 10.1016/j.oraloncology.2020.104722
37Editorial. 2019;12:3 doi: 10.1111/ors.12402
38Ecology of Fear: Spines, Armor and Noxious Chemicals Deter Predators in Cancer and in Nature. 2021;9: doi: 10.3389/fevo.2021.682504
39Immunotherapy – A Novel Facet of Modern Therapeutics. 2021;1 doi: 10.1007/978-981-15-9038-2_1
40ATP stabilised and sensitised calcium phosphate nanoparticles as effective adjuvants for a DNA vaccine against cancer. 2021;9:7435 doi: 10.1039/D1TB01408K
41Active immunotherapy of cancer: An overview of therapeutic vaccines. 2019;69:490 doi: 10.5937/arhfarm1906490F
42Combined strategies for tumor immunotherapy with nanoparticles. 2019;21:1441 doi: 10.1007/s12094-019-02081-3
43Principles of Translational Science in Medicine. 2021;307 doi: 10.1016/B978-0-12-820493-1.00033-7
44Biomaterials for Cancer Therapeutics. 2020;331 doi: 10.1016/B978-0-08-102983-1.00012-0
45Modeling immune cell behavior across scales in cancer. 2020;12: doi: 10.1002/wsbm.1484
46Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. 2019;11:248 doi: 10.1007/s12609-019-00332-4
47Immunostimulatory biomaterials to boost tumor immunogenicity. 2020;8:5516 doi: 10.1039/D0BM01183E
48Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. 2019;9: doi: 10.3389/fonc.2019.00396
49Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. 2021; doi: 10.1007/s10198-021-01337-6
50Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. 2020;37:354 doi: 10.1016/j.ccell.2020.02.001
51Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. 2020;34:749 doi: 10.1007/s40259-020-00450-x
52Antibody–drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management. 2020;52:402 doi: 10.4103/ijp.IJP_475_18
53A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. 2019;18:1081 doi: 10.1158/1535-7163.MCT-18-0737
54Immunotherapy and other systemic therapies for cutaneous SCC. 2019;99:104459 doi: 10.1016/j.oraloncology.2019.104459
55Drug Delivery Devices and Therapeutic Systems. 2021;423 doi: 10.1016/B978-0-12-819838-4.00016-X
56Delivery of a Cancer-Testis Antigen-Derived Peptide Using Conformationally Restricted Dipeptide-Based Self-Assembled Nanotubes. 2021; doi: 10.1021/acs.molpharmaceut.1c00451
57Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab. 2020;7:MMT36 doi: 10.2217/mmt-2019-0020
58O-acetylated Gangliosides as Targets for Cancer Immunotherapy. 2020;9:741 doi: 10.3390/cells9030741
59Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. 2020;20: doi: 10.1186/s12874-020-00997-x
60The discovery of potent small molecule activators of human STING. 2021;209:112869 doi: 10.1016/j.ejmech.2020.112869
61Cancer and the Immune System: The History and Background of Immunotherapy. 2019;35:150923 doi: 10.1016/j.soncn.2019.08.002
62The need for rapid therapeutic efficacy testing for cancer therapy. 2020;113:104382 doi: 10.1016/j.yexmp.2020.104382
63Integrative Nanomedicine for New Therapies. 2020;321 doi: 10.1007/978-3-030-36260-7_12
64Emerging therapeutic agents for advanced non-small cell lung cancer. 2020;13: doi: 10.1186/s13045-020-00881-7
65The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. 2020;10:666 doi: 10.3390/biom10050666
66Immunosuppression. 2020; doi: 10.5772/intechopen.94754
67Molecular and Cell Biology of Cancer. 2019;117 doi: 10.1007/978-3-030-11812-9_7
68Nano-ablative immunotherapy for cancer treatment. 2021;10:3247 doi: 10.1515/nanoph-2021-0171
69Novel therapeutic strategies for spinal osteosarcomas. 2020;64:83 doi: 10.1016/j.semcancer.2019.05.018
70Spontaneous regression of adenocarcinoma of submandibular gland. 2021;87:486 doi: 10.1016/j.bjorl.2020.10.014
71The pint- sized powerhouse: Illuminating the mighty role of the gut microbiome in improving the outcome of anti- cancer therapy. 2021;70:98 doi: 10.1016/j.semcancer.2020.07.012
72Efficacy of immunotherapy with PD-1 inhibitor in colorectal cancer: a meta-analysis. 2020;9:1285 doi: 10.2217/cer-2020-0040
73Recent Advances in the Use of Plant Virus-Like Particles as Vaccines. 2020;12:270 doi: 10.3390/v12030270
74Recent developments in antibody derivatives against colorectal cancer; A review. 2021;265:118791 doi: 10.1016/j.lfs.2020.118791
75Current Applications for Overcoming Resistance to Targeted Therapies. 2019;20:97 doi: 10.1007/978-3-030-21477-7_4
76Cancer: The Enemy from Within. 2020;223 doi: 10.1007/978-3-030-40651-6_9
77Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo. 2020;11:2873 doi: 10.18632/oncotarget.27556
78Burger's Medicinal Chemistry and Drug Discovery. 2021;1 doi: 10.1002/0471266949.bmc157.pub2
79Learning-accelerated discovery of immune-tumour interactions. 2019;4:747 doi: 10.1039/C9ME00036D
80Human health and snails. 2021;42:211 doi: 10.1080/15321819.2020.1844751
81Antitumour metastasis and the antiangiogenic and antitumour effects of a Eimeria stiedae soluble protein. 2021;43: doi: 10.1111/pim.12825
82Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. 2020;112:562 doi: 10.1093/jnci/djaa021
83William B. Coley. 2020;47:413 doi: 10.1016/j.ucl.2020.07.001
84The Microbiome in Health and Disease. 2020;171:301 doi: 10.1016/bs.pmbts.2020.04.004
85Resistance to Targeted Therapies in Lymphomas. 2019;21:155 doi: 10.1007/978-3-030-24424-8_7
86A guide to cancer immunotherapy: from T cell basic science to clinical practice. 2020;20:651 doi: 10.1038/s41577-020-0306-5
87Nanoformulation Strategies for Cancer Treatment. 2021;207 doi: 10.1016/B978-0-12-821095-6.00003-3
88CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. 2020;19:191 doi: 10.1093/bfgp/elz039
89Current trends in cancer immunotherapy: a literature-mining analysis. 2020;69:2425 doi: 10.1007/s00262-020-02630-8
90Translational Biotechnology. 2021;233 doi: 10.1016/B978-0-12-821972-0.00014-9
91Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. 2019;19:2158 doi: 10.2174/1568026619666190904163524
92miRNAs as novel immunoregulators in cancer. 2021; doi: 10.1016/j.semcdb.2021.04.013
93Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications. 2021;22:166 doi: 10.1016/j.omto.2021.08.005
94Nanoparticles: Properties and Applications in Cancer Immunotherapy. 2019;25:1962 doi: 10.2174/1381612825666190708214240
95The Intriguing History of Cancer Immunotherapy. 2019;10: doi: 10.3389/fimmu.2019.02965
96Precision Medicine in Oncology. 2020;133 doi: 10.1002/9781119432487.ch5
© 2016-2021 OAE Publishing Inc., except certain content provided by third parties